Author

Darla Liles

East Carolina UniversityORCID 0000-0003-1480-7887Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Aaron David SchimmeriD· 1 shared Adrienne HellandiD· 1 shared Ahmet A. Kurdoglu· 1 shared Ajai ChariiD· 1 shared Alex Blanski· 1 shared Andrea Donnelly· 1 shared Andrzej J. JakubowiakiD· 1 shared Austin W. Christofferson· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron David SchimmerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyScience AdvancesPeer-reviewedApr 9, 2025

Acute myeloid leukemia mitochondria hydrolyze ATP to resist chemotherapy

James T. Hagen, McLane M. Montgomery, Raphael Taiwo Aruleba…·Kelsey H. Fisher‐Wellman

This study identifies a bioenergetic mechanism in AML cells where mitochondria consume ATP to resist chemotherapy, offering a target for improving treatment.

30 citationstop 2%

humanATAC-seq

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintAug 2, 2021

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Sheri Skerget, Daniel Peñaherrera, Ajai Chari…·Jonathan J. Keats

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

19 citations

humanwhole-exome sequencing

𝕏 PostBluesky